Argenx SE

Argenx, a biotechnology company, will present at upcoming investor conferences, with its stock price fluctuating over the past year and current valuation metrics including a price-to-earnings ratio of 36.59.

Argenx SE’s stock price has surged 31% in the past month, driven by the company’s strong quarterly performance, despite regulatory warnings and a securities investigation.

Argenx SE, a biotech company, partners with tennis legend Monica Seles to raise awareness for myasthenia gravis and support patients with rare diseases.

Argenx SE’s stock price surges following analyst upgrades from Barclays, JPMorgan, and Deutsche Bank, with price targets raised to $220, $200, and $250 respectively.

Argenx SE is under investigation by Pomerantz Law Firm, potentially impacting its stock price and market performance.

Argenx SE, a biotech firm, is under investigation and facing scrutiny from investors and regulatory bodies due to concerns over its financial dealings and corporate governance.

Argenx SE has exceeded expectations with its half-year financial results, with EPS and revenue surpassing forecasts and its market capitalization now exceeding 30 billion euros.

Argenx SE is set to report its half-year 2025 financial results on July 31, 2025, as the biotech sector experiences positive trends despite the company’s relatively stable stock price.

Argenx SE will release its half-year 2025 financial results and second-quarter business update on July 31, 2025.

Argenx SE’s stock price has fluctuated amid regulatory scrutiny over its Vyvgart Hytrulo treatment, but analyst ratings have helped stabilize the stock.